Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model

Virology

Volumn 339, Issue 2, 2005, Pages 164-175

  Meseda, Clement A ^a   Garcia, Alonzo D ^a   Kumar, Arunima ^a   Mayer, Anne E ^a   Manischewitz, Jody ^a   King, Lisa R ^a   Golding, Hana ^a   Merchlinsky, Michael ^a   Weir, Jerry P ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Dryvax; Modified vaccinia virus Ankara; Smallpox vaccination; Vaccine immunogenicity

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALLPOX; VACCINATION; VACCINIA VIRUS; VIRUS INACTIVATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; SMALLPOX VACCINE; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINIA VIRUS;

ANIMALIA; ANKARA; MURINAE; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 23844526887     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2005.06.002     Document Type: Article

References (39)

1. E. Bell, M. Shamim, J.C. Whitbeck, G. Sfyroera, J.D. Lambris, and S.N. Isaacs Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin Virology 325 2 2004 425 431
2. I.M. Belyakov, P. Earl, A. Dzutsev, V.A. Kuznetsov, M. Lemon, L.S. Wyatt, J.T. Snyder, J.D. Ahlers, G. Franchini, B. Moss, and J.A. Berzofsky Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses Proc. Natl. Acad. Sci. U.S.A. 100 16 2003 9458 9463
3. T.J. Blanchard, A. Alcami, P. Andrea, and G.L. Smith Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine J. Gen. Virol. 79 Pt 5 1998 1159 1167
4. E.A. Boulter, H.T. Zwartouw, D.H. Titmuss, and H.B. Maber The nature of the immune state produced by inactivated vaccinia virus in rabbits Am. J. Epidemiol. 94 6 1971 612 620
5. M. Bray, M. Martinez, D.F. Smee, D. Kefauver, E. Thompson, and J.W. Huggins Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge J. Infect. Dis. 181 1 2000 10 19
6. M.W. Carroll, and B. Moss Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line Virology 238 2 1997 198 211
7. S. Chakrabarti, J.R. Sisler, and B. Moss Compact, synthetic, vaccinia virus early/late promoter for protein expression BioTechniques 23 6 1997 1094 1097
8. R.M. Conry, M.B. Khazaeli, M.N. Saleh, K.O. Allen, D.L. Barlow, S.E. Moore, D. Craig, R.B. Arani, J. Schlom, and A.F. LoBuglio Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration Clin. Cancer Res. 5 9 1999 2330 2337
9. I. Drexler, K. Heller, B. Wahren, V. Erfle, and G. Sutter Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells J. Gen. Virol. 79 Pt 2 1998 347 352
10. P. Earl, N. Cooper, L. Wyatt, B. Moss, and M. Carroll Preparation of cell cultures and vaccinia virus stocks F.M. Ausubel R. Brent R.E. Kingston D.D. Moore J.G. Seidman J. Smith K. Struhl Current Protocols in Molecular Biology vol. 3 1998 John Wiley and Sons Inc. New York 16.16.1 16.16.13 4 vols
11. P.L. Earl, J.L. Americo, L.S. Wyatt, L.A. Eller, J.C. Whitbeck, G.H. Cohen, R.J. Eisenberg, C.J. Hartmann, D.L. Jackson, D.A. Kulesh, M.J. Martinez, D.M. Miller, E.M. Mucker, J.D. Shamblin, S.H. Zwiers, J.W. Huggins, P.B. Jahrling, and B. Moss Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox Nature 428 6979 2004 182 185
12. F. Fenner, D.A. Henderson, I. Arita, Z. Jezek, and I.D. Ladnyi Smallpox and its Eradication 1988 World Halth Organization Geneva
13. C. Fogg, S. Lustig, J.C. Whitbeck, R.J. Eisenberg, G.H. Cohen, and B. Moss Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions J. Virol. 78 19 2004 10230 10237
14. M.C. Galmiche, J. Goenaga, R. Wittek, and L. Rindisbacher Neutralizing and protective antibodies directed against vaccinia virus envelope antigens Virology 254 1 1999 71 80
15. C.V. Hanson, J.L. Riggs, and E.H. Lennette Photochemical inactivation of DNA and RNA viruses by psoralen derivatives J. Gen. Virol. 40 2 1978 345 358
16. D.A. Henderson Bioterrorism as a public health threat Emerg. Infect. Dis. 4 3 1998 488 492
17. D.A. Henderson The looming threat of bioterrorism Science 283 5406 1999 1279 1282
18. D.A. Henderson, and B. Moss Smallpox and vaccinia S.A. Plotkin J.M. Orenstein Vaccines 3rd ed. 1999 W.B. Sanders Company Philadelphia 74 97
19. J.W. Hooper, D.M. Custer, C.S. Schmaljohn, and A.L. Schmaljohn DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge Virology 266 2 2000 329 339
20. J.W. Hooper, D.M. Custer, and E. Thompson Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates Virology 306 1 2003 181 195
21. J.W. Hooper, E. Thompson, C. Wilhelmsen, M. Zimmerman, M.A. Ichou, S.E. Steffen, C.S. Schmaljohn, A.L. Schmaljohn, and P.B. Jahrling Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox J. Virol. 78 9 2004 4433 4443
22. E.H. Lennette General principles underlying laboratory diagnosis of virus and rickettsial infections E.H. Lennette N.J. Schmidt Diagnostic Procedures of Virus and Rickettsial Disease 1964 American Public Health Association New York 45
23. S. Lustig, C. Fogg, J.C. Whitbeck, and B. Moss Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement Virology 328 1 2004 30 35
24. J. Manischewitz, L.R. King, N.A. Bleckwenn, J. Shiloach, R. Taffs, M. Merchlinsky, N. Eller, M.G. Mikolajczyk, D.J. Clanton, T. Monath, R.A. Weltzin, D.E. Scott, and H. Golding Development of a novel vaccinia-neutralization assay based on reporter-gene expression J. Infect. Dis. 188 3 2003 440 448
25. M.J. Martinez, M.P. Bray, and J.W. Huggins A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system Arch. Pathol. Lab. Med. 124 3 2000 362 377
26. A. Mayr, H. Stickl, H.K. Muller, K. Danner, and H. Singer [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)] Zentralbl. Bakteriol. [B] 167 5-6 1978 375 390
27. R. McKenzie Clinical applications of jet injection N. Z. Med. J. 95 720 1982 815 817
28. C.A. Meseda, K.L. Elkins, M.J. Merchlinsky, and J.P. Weir Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone J. Infect. Dis. 186 8 2002 1065 1073
29. S.R. Rosenthal, M. Merchlinsky, C. Kleppinger, and K.L. Goldenthal Developing new smallpox vaccines Emerg. Infect. Dis. 7 6 2001 920 926
30. J. Schriewer, R.M. Buller, and G. Owens Mouse models for studying orthopoxvirus respiratory infections Methods Mol. Biol. 269 2004 289 308
31. C. Smerdou, and P. Liljestrom Two-helper RNA system for production of recombinant Semliki forest virus particles J. Virol. 73 2 1999 1092 1098
32. J.T. Snyder, I.M. Belyakov, A. Dzutsev, F. Lemonnier, and J.A. Berzofsky Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses J. Virol. 78 13 2004 7052 7060
33. H. Stickl, V. Hochstein-Mintzel, A. Mayr, H.C. Huber, H. Schafer, and A. Holzner MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl) Dtsch. Med. Wochenschr. 99 47 1974 2386 2392
34. D.C. Tscharke, and G.L. Smith A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae J. Gen. Virol. 80 Pt 10 1999 2751 2755
35. D.C. Tscharke, P.C. Reading, and G.L. Smith Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes J. Gen. Virol. 83 Pt 8 2002 1977 1986
36. G.S. Turner Respiratory infection of mice with vaccinia virus J. Gen. Virol. 1 3 1967 399 402
37. G.S. Turner, and E.J. Squires Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus J. Gen. Virol. 13 1 1971 19 25
38. J.D. Williamson, R.W. Reith, L.J. Jeffrey, J.R. Arrand, and M. Mackett Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route J. Gen. Virol. 71 Pt 1 1990 2761 2767
39. L.S. Wyatt, P.L. Earl, L.A. Eller, and B. Moss Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge Proc. Natl. Acad. Sci. U.S.A. 101 13 2004 4590 4595